2020/21 Pathway Transformation Fund - UPDATE (15 January 2021)

Applications for phase three of the Pathway Transformation Fund (PTF) are now open. 

CLOSING DATE EXTENDED: the PTF submission window has been extended to 30 April to
allow an extra 10 weeks to submit applications and breathing space whilst we
are in full Covid-19 mode

The fund supports NHS organisations increase adoption of the 2020/21 Rapid Uptake Products RUPs, which are:

• Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
• Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
• Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

The PTF can help providers overcome practical obstacles to introducing these products, such as:

• Support set-up costs such as training and accreditation of staff;
• Pathway redesign and/or business support expertise;
• Providing funding for specialist nurses and clinical staff needed to implement a new part of the procedure; and
• Covering double running costs
• Capital costs.

NHS organisations will be able to submit applications for PTF from 4 January until 12-noon, 30 April 2021. 

Please contact us for support with developing and submission of applications.